ENTA
Enanta Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $216.34M | Price | $14.73 |
| Volume | 254.94K | Change | +4.17% |
| P/E Ratio | -1.9 | Open | $14.13 |
| Revenue | $67.6M | Prev Close | $14.14 |
| Net Income | $-116.0M | 52W Range | $4.09 - $15.34 |
| Div Yield | N/A | Target | $16.67 |
| Overall | 49 | Value | 60 |
| Quality | 23 | Technical | 66 |
No chart data available
About Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Latest News
KeyBanc Keeps Their Buy Rating on Central Garden Pet (CENT)
Canaccord Genuity Keeps Their Buy Rating on Central Garden Pet (CENT)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENTA | $14.73 | +4.2% | 254.94K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enanta Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW